BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20126847)

  • 1. [Prostate carcinoma and testosterone: risks and controversies].
    Rhoden EL; Averbeck MA
    Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):956-62. PubMed ID: 20126847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone therapy and prostate carcinoma.
    Rhoden EL; Averbeck MA
    Curr Urol Rep; 2009 Nov; 10(6):453-9. PubMed ID: 19863857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen replacement in men undergoing treatment for prostate cancer.
    Rhoden EL; Averbeck MA; Teloken PE
    J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
    Meza J; Weaver K; Martin S
    Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
    Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
    J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone Therapy Among Prostate Cancer Survivors.
    Nguyen TM; Pastuszak AW
    Sex Med Rev; 2016 Oct; 4(4):376-88. PubMed ID: 27474995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is testosterone a friend or a foe of the prostate?
    Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
    J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone therapy for men at risk for or with history of prostate cancer.
    Morgentaler A
    Curr Treat Options Oncol; 2006 Sep; 7(5):363-9. PubMed ID: 16904053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of testosterone replacement therapy following radical prostatectomy.
    Khera M; Lipshultz LI
    Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone replacement therapy and the risk of prostate cancer.
    Warburton D; Hobaugh C; Wang G; Lin H; Wang R
    Asian J Androl; 2015; 17(6):878-81; discussion 880. PubMed ID: 25865848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone administration in older men.
    Matsumoto AM
    Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
    J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men.
    Rosen RC; Wu FC; Behre HM; Roehrborn CG; Schröder FH; Siami FS; Martha JF; Finn JD; Araujo AB
    Aging Male; 2013 Mar; 16(1):1-7. PubMed ID: 23373674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK; Oefelein MG
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
    Morales A
    BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.